MEDI7247

DRUG2 trials

Sponsors

MedImmune LLC

Conditions

Acute Myeloid LeukemiaColorectal Cancer (CRC)Diffuse Large B-cell LymphomaHead and Neck Squamous Cell Carcinoma (HNSCC)Metastatic Castration-resistant Prostate Cancer (mCRPC)Multiple MyelomaNon Small Cell Lung Cancer Squamous (NSCLC-Sq)Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

CompletedNCT03106428

MedImmune LLCAcute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Multiple Myeloma

Start: 2017-03-29End: 2020-01-03Updated: 2020-02-28

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

CompletedNCT03811652

MedImmune LLCColorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Metastatic Castration-resistant Prostate Cancer (mCRPC) +3

Start: 2018-12-20End: 2019-12-10Updated: 2019-12-30

Related Papers

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study

Targeted Oncology2024-04-299 citations

Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody–Drug Conjugate

Antibodies2023-10-1711 citations

Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers

Blood2018-11-299 citations

A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.

Journal of Clinical Oncology2018-05-201 citations